Unlock instant, AI-driven research and patent intelligence for your innovation.
Polyethylene glycol-modified integrin blocking agent HM-3 and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
An integrin blocker, HM-3 technology, applied in the field of medicine to achieve the effect of inhibiting tumor growth and metastasis, and inhibiting tumor angiogenesis
Inactive Publication Date: 2012-04-18
CHINA PHARM UNIV
View PDF1 Cites 44 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
The research on PEG modification of synthetic small molecule peptides started late, but it has attracted the attention of many researchers
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
[0042] The solid-phase synthesis method of Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Gly-Arg-Gly-Asp, which uses Fmoc-Ile-wang resin or Fmoc-Ile-CTC resin is used as the starting material, and then dipeptide to octadecapeptide are sequentially connected with protected amino acids. After the peptide connection is completed, it is fully washed, and then the peptide is cut and post-treated to obtain the crude product of HM-3. Purify the crude product by first dissolving it, then using preparative high-performance liquid phase for two purifications, and finally concentrating and freeze-drying to obtain the pure product.
[0043] Specific steps are as follows:
[0044] 1. Synthesis:
[0045] Weigh 14.7g of Fmoc-Ile-Wang resin, pour it into a 1L reaction column with glass sand core, add CH 2 Cl 2 147ml to fully expand the resin.
[0070] Embodiment 2 The step of polyethylene glycol modification polypeptide
[0071] mPEG-SC 20K Reaction with HM-3
[0072] Weigh 2gmPEG-SC respectively 20K and 106.24mg of HM-3 (molar ratio 1.5:1) were placed in 40ml-100ml of prepared PBS buffer solution of pH 5-8.5, and reacted overnight at 4°C. PEG-SC500-20000 can be linked according to Example 2 to synthesize modified polypeptides.
Embodiment 3
[0073] Embodiment 3 separation and purification steps
[0074] 1. Separation
[0075] The sample after the reaction was purified by semi-preparative high-performance liquid phase (HPLC, BIO-RAD), and the purification conditions were:
[0076] Mobile phase: ACN (+0.1% TFA), H 2 O(+0.1%TFA); ACN linear gradient: 40%-95%;
[0080] During the eluting process of the target peak, collect the product with a centrifuge tube.
[0081] 2. Purification
[0082] The product collected by HPLC was first pre-frozen overnight in a -70°C low-temperature refrigerator, and then freeze-dried in a freeze dryer that had been cooled in advance until it was completely white powder by visual inspection (about 30 hours). Harvest the freeze-dried product, weigh and record the weight of the product and store it...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention relates to the field of medicaments, in particular to an integrin blocking agent HM-3 which has the function of inhibiting tumor angiogenesis, integrin affinity and a bonding capacity and application thereof. The blocking agent is a polypeptide modified with polyethylene glycol, and the modified integrin blocking agent polypeptide can be applied to treatment of solid tumors. During application of the integrin blocking agent to preparation of a tumor treatment medicament, the sequence and structure of the integrin blocking agent is mPEG-SC20k-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp. The integrin blocking agent polypeptide designed in the invention is scientific, reasonable, practical and effective, can be used for preparing a treatment medicament for treating human solid tumors, and has remarkable social value and market value; and the treatment spectrum of the integrin blocking agent is expanded greatly, and novel thought and prospect are provided for future development of medicaments.
Description
technical field [0001] The present invention relates to the field of medicine, in particular to an integrin blocker capable of inhibiting tumor angiogenesis, and having integrin affinity and binding ability. The blocker is a polyethylene glycol modified polypeptide, and the integrin blocker The interrupting agent polyethylene glycol modified polypeptide can be used for the treatment of solid tumors. Background technique [0002] Studies have shown that the growth of solid tumors depends on angiogenesis, and angiogenesis can not only provide the nutrients and oxygen needed by the tumor, excrete metabolites, but also serve as a way for distant metastasis. Therefore, blocking neovascularization may be a means to prevent tumor growth and metastasis, thereby motivating extensive research on pro-angiogenic and anti-angiogenic molecules. [0003] Compared with traditional tumor treatment drugs, the biggest advantages of tumor angiogenesis inhibitors are: ①Selective action on vascu...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.